SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

CytRx Oncology Corp – ‘8-K’ for 6/29/07

On:  Friday, 6/29/07, at 5:23pm ET   ·   For:  6/29/07   ·   Accession #:  950144-7-6247   ·   File #:  0-51534

Previous ‘8-K’:  ‘8-K’ on / for 6/7/07   ·   Next:  ‘8-K’ on 7/27/07 for 7/25/07   ·   Latest:  ‘8-K’ on 6/18/08 for 6/16/08

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/29/07  CytRx Oncology Corp               8-K:7,9     6/29/07    2:1.2M                                   Bowne of Atlanta Inc/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Innovive Pharmaceuticals, Inc.                      HTML     16K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     31K

8-K   —   Innovive Pharmaceuticals, Inc.
Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
"Table of Contents
"Item 7.01. Regulation FD Disclosure
"Item 9.01. Financial Statements and Exhibits
"Signatures

This is an HTML Document rendered as filed.  [ Alternative Formats ]

  Innovive Pharmaceuticals, Inc.  
Table of Contents

 
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 29, 2007
INNOVIVE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   000-51534   74-3123261
 
(State or other jurisdiction of incorporation)   (Commission File
Number) 		  (IRS Employer ID Number)
     
555 Madison Avenue, 25th Floor, New York, New York   10022
 
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code (212) 716-1810
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 7.01. Regulation FD Disclosure
Item 9.01. Financial Statements and Exhibits
SIGNATURES
Exhibit 99.1

Table of Contents

Item 7.01. Regulation FD Disclosure.
Innovive Pharmaceuticals, Inc. is furnishing as an exhibit to this Form 8-K a PowerPoint presentation of its most recent corporate overview. The overview includes updates regarding efficacy and safety for INNO-406 and the development plan for INNO-406, as well as fast-track designation for tamibarotene (INNO-507). The corporate overview will be available on Innovive’s website at www.innovivepharma.com.
The information furnished in this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
     
Exhibit    
Number   Description of Document
99.1
  PowerPoint presentation of corporate overview dated June 29, 2007

2

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
 
  INNOVIVE PHARMACEUTICALS, INC.    
 
        
Date: June 29, 2007
  /s/ J. Gregory Jester
 
J. Gregory Jester 		   
 
  Chief Financial Officer    

3

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period End:6/29/07424B3
 List all Filings 
↑Top
Filing Submission 0000950144-07-006247   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., Apr. 25, 8:57:48.1am ET